Yahoo
OTC Markets OTCQB - Delayed Quote USD

Guided Therapeutics, Inc. (GTHP)

0.1000 0.0000 (0.00%)
At close: November 6 at 4:00:00 PM EST
Chart Range Bar
Loading chart for GTHP
  • Previous Close 0.1000
  • Open 0.1000
  • Bid 0.1000 x 570000
  • Ask 0.1100 x 3000000
  • Day's Range 0.1000 - 0.1010
  • 52 Week Range 0.1000 - 0.5400
  • Volume 53,000
  • Avg. Volume 36,804
  • Market Cap (intraday) 9.654M
  • Beta (5Y Monthly) 0.81
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0400
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Moby Rating Neutral

Guided Therapeutics, Inc., a medical technology company, researches, develops, tests, manufactures, sells, and distributes medical devices in the United States and internationally. It offers LuViva, an advanced cervical scan non-invasive cervical cancer detection device that provides less invasive and painless alternative to conventional tests for identifying, screening, and detecting cervical cancers and precancers. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is headquartered in Peachtree Corners, Georgia.

www.guidedinc.com

3

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

GTHP
81.48%
S&P 500 (^GSPC)
7.76%

1-Year Return

GTHP
60.00%
S&P 500 (^GSPC)
9.77%

3-Year Return

GTHP
33.33%
S&P 500 (^GSPC)
68.96%

5-Year Return

GTHP
80.00%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share (Normalized)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY13
Revenue 144k
Earnings --
Profit Margin 0.00%

Q2

FY02

Q4

FY12

Q1

FY13

Q3

FY13

0
200K
400K
600K
800K
1M
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -115.63%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    650k

  • Net Income Avi to Common (ttm)

    -3.64M

  • Diluted EPS (ttm)

    -0.0400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    12k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.05M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: